FALSE POSITIVITY WITH THIRD-GENERATION (MONOCLONAL) ASSAY FOR HEPATITIS B SURFACE ANTIGEN

The Lancet ◽  
1988 ◽  
Vol 331 (8580) ◽  
pp. 299-300 ◽  
Author(s):  
IanJ. Skurrie ◽  
SuzanneM. Garland
Vaccine ◽  
2019 ◽  
Vol 37 (40) ◽  
pp. 5954-5961 ◽  
Author(s):  
Thuy Trang Nguyen ◽  
Jung-ah Choi ◽  
Ji Seok Kim ◽  
Hayan Park ◽  
Eunji Yang ◽  
...  

BMJ ◽  
1985 ◽  
Vol 291 (6498) ◽  
pp. 780-782 ◽  
Author(s):  
P Wantzin ◽  
J O Nielsen ◽  
N Tygstrup ◽  
H Soerensen ◽  
E Dybkjaer

1977 ◽  
Author(s):  
Clyde B. McAuley

It is well recognized that the safety of biological products prepared from blood, such as ProfilateR, a freeze-dried factor VIII concentrate, may be increased by testing for hepatitis B surface antigen.Abbott Laboratories has been routinely screening all plasma donations for hepatitis B surface antigen since January, 1971. Originally, the screening was performed using the second generation counter-immunoelectrophoresis technique, AUS-tect. In April, 1973, the counter-immunoelectrophoresis testing was replaced with the more sensitive third generation radioimmunoassay technique, Aus-RIA, for routine hepatitis B surface antigen testing. The most sensitive current radioimmunoassay technique, Aus-RIA II, has been used since February, 1975. This presentation will review the results of six years of testing experience. The data indicate that the incidence of positive donors in the commercial plasmapheresis system is 1.4 per 1,000, similar to that reported for a volunteer blood program.


1981 ◽  
Vol 47 (2) ◽  
pp. 145-159 ◽  
Author(s):  
Howard A. Fields ◽  
Candace L. Davis ◽  
Gordon R. Dressman ◽  
Daniel W. Bradley ◽  
James E. Maynard

2015 ◽  
Vol 41 (08) ◽  
Author(s):  
E Reuss ◽  
N Evers ◽  
N Dietrich ◽  
J Vollmar ◽  
PM Schneider ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document